120-OR: Efficacy of Tirzepatide in Achieving the Composite Endpoints of Glycemic, Blood Pressure, and Lipid Goals in SURMOUNT-2

• Published in: Diabetes (New York, N.Y.) Vol. 73; p. 1
• Main Authors: Sattar, Naveed, Cheng, Alice YY, Benabbad, Imane, Lee, Clare, See, Sophia Kyoungah, Leech, John, Mojdami, Donna
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2024
• Subjects: Antidiabetics; Blood pressure; Body weight; Body weight loss; Diabetes mellitus (non-insulin dependent); High density lipoprotein; Lipids; Obesity; Overweight; Physical activity; Weight control

In the SURMOUNT-2 (SM-2) trial of adults with overweight/obesity and type 2 diabetes (T2D), tirzepatide (TZP), a once weekly GIP/GLP-1 receptor agonist, significantly reduced body weight (BW) in conjunction with a reduced calorie diet and increased physical activity. This post-hoc analysis assessed...